Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
Last trade$3.69
Day change-$0.075 (-1.99%)
Day range$3.67 – $3.81
Volume1,553,343
Market cap$473M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$472.59M
Price / earnings
—
Price / book
-6.67×
Price / sales
9.68×
EV / sales
8.87×
EV / EBITDA
-7.65×
Profitability
Earnings per share
-$0.63
Return on assets
-66.44%
Return on equity
111.94%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-0.72×
Current ratio
6.12×
Quick ratio
5.69×
Cash ratio
5.22×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$40.7M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for AQST, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$7.56M
$13.82M
$14.45M
$13.02M
$12.81M
$10M
$8.72M
$11.87M
Cost of revenue
$3.61M
$4.02M
$3.47M
$5.84M
$4.51M
$4.56M
$3.65M
$4.52M
Gross profit
$3.95M
$9.8M
$10.98M
$7.18M
$8.3M
$5.44M
$5.07M
$7.35M
Selling, general and administrative
$14.17M
$14.06M
$10.98M
$32.82M
$15.25M
$12.71M
$19.07M
$16.01M
Research and development
$4.25M
$3.96M
$4.2M
$3.2M
$4.53M
$4.11M
$5.36M
$4.92M
Total operating expenses
$18.42M
$18.03M
$15.18M
$37.45M
$19.78M
$16.81M
$24.43M
$22.31M
Operating income
-$14.47M
-$8.22M
-$4.2M
-$30.27M
-$11.48M
-$11.37M
-$19.37M
-$14.96M
Interest expense
-$2.88M
-$3.84M
-$3.94M
-$2.84M
-$4.27M
-$4.28M
-$4.28M
-$2.84M
Income before taxes
-$16.5M
-$22.86M
-$8.06M
-$31.86M
-$15.45M
-$13.55M
-$22.93M
-$17.07M
Income taxes
$0
$0
$0
$0
$0
$0
$0
-$14K
Net income
-$16.5M
-$22.86M
-$8.06M
-$31.86M
-$15.45M
-$13.55M
-$22.93M
-$17.06M
Net income attributable to common shareholders
-$16.5M
-$22.86M
-$8.06M
-$31.86M
-$15.45M
-$13.55M
-$22.93M
-$17.06M
EBITDA
-$14.31M
-$8.09M
-$4.09M
-$30.14M
-$11.34M
-$11.23M
-$19.23M
-$14.82M
Basic earnings per share
-$0.13
-$0.18
-$0.07
-$0.26
-$0.14
-$0.14
-$0.24
-$0.19
Diluted earnings per share
-$0.13
-$0.18
-$0.07
-$0.26
-$0.14
-$0.14
-$0.24
-$0.19
Recent news
Company coverage with links to the original publishers.
Aquestive Therapeutics announced that the FDA has accepted its resubmission of the New Drug Application (NDA) for Anaphylm™ (dibutepinephrine) sublingual film for treating Type I allergic reactions and anaphylaxis. The FDA assigned a PDUFA goal date of March 16, 2027, classified as a Class 2 response. If approved, Anaphylm would be the first and only oral rescue medication for severe allergic reactions. The company is also advancing its Canadian regulatory submission planned for Q4 2026.
Rosen Law Firm reminds investors in Aquestive Therapeutics (AQST) who purchased securities between June 16, 2025 and January 8, 2026 of the May 4, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Aquestive made false or misleading statements regarding its New Drug Application for Anaphylm, specifically concealing human factors issues related to packaging, use, administration, and labeling of its sublingual film product.
A class action lawsuit has been filed against Atara Biotherapeutics alleging securities fraud. The complaint claims the company made false statements about manufacturing issues and deficiencies in the ALLELE study that would likely prevent FDA approval of tabelecleucel. Investors who purchased Atara securities between May 20, 2024 and January 9, 2026 may be eligible to join the case.
A class action lawsuit has been filed against Aquestive Therapeutics for allegedly misleading investors about FDA approval prospects for its Anaphylm drug. The company failed to disclose FDA-identified deficiencies that precluded approval by the January 31, 2026 PDUFA date. Following the January 9, 2026 announcement of these deficiencies, Aquestive's stock price plummeted 37% from $6.21 to $3.91 per share. Investors who purchased shares between June 16, 2025 and January 8, 2026 have until May 4, 2026 to apply as lead plaintiff.
The Portnoy Law Firm has announced a class action lawsuit against Aquestive Therapeutics on behalf of investors who purchased securities between June 16, 2025 and January 8, 2026. The lawsuit alleges that Aquestive made false statements about its Anaphylm drug approval prospects and failed to disclose FDA-identified deficiencies in the NDA application. Following the January 9, 2026 disclosure of these deficiencies, Aquestive's stock price fell more than 37%. The deadline for filing a lead plaintiff motion is May 4, 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.